免疫治疗在晚期或复发性宫颈癌治疗中的研究进展
Research Progress of Immunotherapy in the Treatment of Advanced or Recurrent Cervical Cancer
DOI: 10.12677/acm.2024.14123253, PDF,   
作者: 马嘉欣：内蒙古医科大学第一临床医学院，内蒙古 呼和浩特；张姝凤, 孙晓革*：内蒙古医科大学附属医院放疗科，内蒙古 呼和浩特
关键词: 宫颈癌；免疫联合治疗；放疗；化疗；靶向治疗；疗效；Cervical Cancer； Combined Immunotherapy； Radiotherapy； Chemotherapy； Targeted Therapy； Curative Effect
摘要: 宫颈癌是妇科最常见的恶性肿瘤之一，以铂类为基础的同步放化疗是局部晚期宫颈癌的标准治疗，而晚期、转移性或复发性宫颈癌的治疗以全身治疗为主。近些年，随着免疫治疗的发展，免疫联合治疗(联合化疗、放疗、靶向等)成为研究热点，为晚期宫颈癌的治疗提供了新的方向，本文就与宫颈癌治疗相关的免疫检查点抑制剂的作用机制以及免疫联合传统治疗方式在晚期或复发性宫颈癌治疗中的研究进展进行综述，希望可以为晚期或复发性宫颈癌患者的治疗提供有价值的参考。
Abstract: Cervical cancer is one of the most common malignant tumors in gynecology, and platinum-based simultaneous radiotherapy is the standard treatment for locally advanced cervical cancer, while systemic therapy is the mainstay of treatment for advanced, metastatic or recurrent cervical cancer. In recent years, with the development of immunotherapy, combined immunotherapy (combined chemotherapy, radiotherapy, targeting, etc.) has become a research hotspot, which provides a new direction for the treatment of advanced cervical cancer. This article provides a review of the mechanism of immune checkpoint inhibitors related to the treatment of cervical cancer as well as the progress of immune-combination therapy with traditional therapeutic modalities in the treatment of advanced or recurrent cervical cancer in the hope of providing useful information for the treatment of patients with advanced or recurrent cervical cancer.
文章引用：马嘉欣, 张姝凤, 孙晓革. 免疫治疗在晚期或复发性宫颈癌治疗中的研究进展[J]. 临床医学进展, 2024, 14(12): 1550-1558. https://doi.org/10.12677/acm.2024.14123253

参考文献

[1] Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. [Google Scholar] [CrossRef] [PubMed]
[2] Koh, W., Abu-Rustum, N.R., Bean, S., Bradley, K., Campos, S.M., Cho, K.R., et al. (2019) Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 64-84. [Google Scholar] [CrossRef] [PubMed]
[3] Kokka, F., Bryant, A., Olaitan, A., Brockbank, E., Powell, M. and Oram, D. (2022) Hysterectomy with Radiotherapy or Chemotherapy or both for Women with Locally Advanced Cervical Cancer. Cochrane Database of Systematic Reviews, 8, CD010260. [Google Scholar] [CrossRef] [PubMed]
[4] 李英, 程忠平. 复发性宫颈癌免疫治疗的研究进展[J]. 中国妇产科临床杂志, 2023, 24(1): 108-110.
[5] Wendel Naumann, R. and Leath, C.A. (2020) Advances in Immunotherapy for Cervical Cancer. Current Opinion in Oncology, 32, 481-487. [Google Scholar] [CrossRef] [PubMed]
[6] O’Neill, R.E. and Cao, X. (2019) Co-Stimulatory and Co-Inhibitory Pathways in Cancer Immunotherapy. In: Advances in Cancer Research, Elsevier, 145-194. [Google Scholar] [CrossRef] [PubMed]
[7] Aghbash, P.S., Hemmat, N., Fathi, H. and Baghi, H.B. (2022) Monoclonal Antibodies in Cervical Malignancy-Related HPV. Frontiers in Oncology, 12, Article ID: 904790. [Google Scholar] [CrossRef] [PubMed]
[8] Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article ID: 964442. [Google Scholar] [CrossRef] [PubMed]
[9] Gennigens, C., Jerusalem, G., Lapaille, L., De Cuypere, M., Streel, S., Kridelka, F., et al. (2022) Recurrent or Primary Metastatic Cervical Cancer: Current and Future Treatments. ESMO Open, 7, Article ID: 100579. [Google Scholar] [CrossRef] [PubMed]
[10] De Giglio, A., Di Federico, A., Nuvola, G., Deiana, C. and Gelsomino, F. (2021) The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines). Current Oncology Reports, 23, Article No. 126. [Google Scholar] [CrossRef] [PubMed]
[11] Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. [Google Scholar] [CrossRef] [PubMed]
[12] Han, X., Chang, W. and Xia, X. (2022) Immune Checkpoint Inhibitors in Advanced and Recurrent/Metastatic Cervical Cancer. Frontiers in Oncology, 12, Article ID: 996495. [Google Scholar] [CrossRef] [PubMed]
[13] Wojtukiewicz, M.Z., Rek, M.M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A.M., et al. (2021) Inhibitors of Immune Checkpoints—Pd-1, PD-L1, CTLA-4—New Opportunities for Cancer Patients and a New Challenge for Internists and General Practitioners. Cancer and Metastasis Reviews, 40, 949-982. [Google Scholar] [CrossRef] [PubMed]
[14] Chauvin, J. and Zarour, H.M. (2020) TIGIT in Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e000957. [Google Scholar] [CrossRef] [PubMed]
[15] Wen, J., Mao, X., Cheng, Q., Liu, Z. and Liu, F. (2021) A Pan-Cancer Analysis Revealing the Role of TIGIT in Tumor Microenvironment. Scientific Reports, 11, Article No. 22502. [Google Scholar] [CrossRef] [PubMed]
[16] Ge, Z., Peppelenbosch, M.P., Sprengers, D. and Kwekkeboom, J. (2021) TIGIT, the Next Step towards Successful Combination Immune Checkpoint Therapy in Cancer. Frontiers in Immunology, 12, Article ID: 699895. [Google Scholar] [CrossRef] [PubMed]
[17] Mauricio, D., Zeybek, B., Tymon-Rosario, J., Harold, J. and Santin, A.D. (2021) Immunotherapy in Cervical Cancer. Current Oncology Reports, 23, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[18] Tewari, K.S., Sill, M.W., Penson, R.T., Huang, H., Ramondetta, L.M., Landrum, L.M., et al. (2017) Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240). The Lancet, 390, 1654-1663. [Google Scholar] [CrossRef] [PubMed]
[19] Tewari, K.S., Monk, B.J., Vergote, I., Miller, A., de Melo, A.C., Kim, H., et al. (2022) Survival with Cemiplimab in Recurrent Cervical Cancer. New England Journal of Medicine, 386, 544-555. [Google Scholar] [CrossRef] [PubMed]
[20] Frenel, J., Le Tourneau, C., O’Neil, B., Ott, P.A., Piha-Paul, S.A., Gomez-Roca, C., et al. (2017) Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results from the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology, 35, 4035-4041. [Google Scholar] [CrossRef] [PubMed]
[21] Chung, H.C., Ros, W., Delord, J., Perets, R., Italiano, A., Shapira-Frommer, R., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478. [Google Scholar] [CrossRef] [PubMed]
[22] Morad, G., Helmink, B.A., Sharma, P. and Wargo, J.A. (2022) Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade. Cell, 185, 576. [Google Scholar] [CrossRef] [PubMed]
[23] Oaknin, A., Moore, K.N., Meyer, T., González, J.L., Devriese, L., Amin, A., et al. (2022) 520MO Safety and Efficacy of Nivolumab (NIVO) ± Ipilimumab (IPI) in Patients (pts) with Recurrent/Metastatic Cervical Cancer (R/M Cx Ca) in Checkmate 358. Annals of Oncology, 33, S782. [Google Scholar] [CrossRef] 
[24] O’Malley, D.M., Neffa, M., Monk, B.J., Melkadze, T., Huang, M., Kryzhanivska, A., et al. (2022) Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of Clinical Oncology, 40, 762-771. [Google Scholar] [CrossRef] [PubMed]
[25] Lee, J., Wu, L., Boonyapipat, S., Kim, H.S., Lee, J., Wang, L., et al. (2023) 744MO Advantig-202: Phase II Randomized, Multicenter, Open-Label Study of Tislelizumab (TIS) with or without Ociperlimab (OCI) in Patients (pts) with Previously Treated Recurrent/metastatic (R/M) Cervical Cancer (CC). Annals of Oncology, 34, S509-S510. [Google Scholar] [CrossRef] 
[26] Zhao, Y., Ma, Y., Zang, A., Cheng, Y., Zhang, Y., Wang, X., et al. (2023) First-in-Human Phase I/Ib Study of QL1706 (PSB205), a Bifunctional PD1/CTLA4 Dual Blocker, in Patients with Advanced Solid Tumors. Journal of Hematology & Oncology, 16, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
[27] Gao, X., Xu, N., Li, Z., Shen, L., Ji, K., Zheng, Z., et al. (2023) Safety and Antitumour Activity of Cadonilimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, for Patients with Advanced Solid Tumours (COMPASSION-03): A Multicentre, Open-Label, Phase 1b/2 Trial. The Lancet Oncology, 24, 1134-1146. [Google Scholar] [CrossRef] [PubMed]
[28] Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., et al. (2017) Prospects for Combining Targeted and Conventional Cancer Therapy with Immunotherapy. Nature Reviews Cancer, 17, 286-301. [Google Scholar] [CrossRef] [PubMed]
[29] Nishio, S., Yonemori, K., Usami, T., Minobe, S., Yunokawa, M., Iwata, T., et al. (2022) Pembrolizumab plus Chemotherapy in Japanese Patients with Persistent, Recurrent or Metastatic Cervical Cancer: Results from KEYNOTE‐826. Cancer Science, 113, 3877-3887. [Google Scholar] [CrossRef] [PubMed]
[30] Wang, J., Lou, H., Cai, H., Huang, X., Li, G., Wang, L., et al. (2022) A Study of AK104 (an Anti-PD1 and Anti-CTLA4 Bispecific Antibody) Combined with Standard Therapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (R/M CC). Journal of Clinical Oncology, 40, 106. [Google Scholar] [CrossRef] 
[31] 孔北华, 刘继红, 殷爱军, 等. 妇科肿瘤免疫检查点抑制剂临床应用指南(2023版) [J]. 现代妇产科进展, 2023, 32(5): 321-348.
[32] Eriksson, D. and Stigbrand, T. (2010) Radiation-Induced Cell Death Mechanisms. Tumor Biology, 31, 363-372. [Google Scholar] [CrossRef] [PubMed]
[33] Lee, L. and Matulonis, U. (2019) Immunotherapy and Radiation Combinatorial Trials in Gynecologic Cancer: A Potential Synergy? Gynecologic Oncology, 154, 236-245. [Google Scholar] [CrossRef] [PubMed]
[34] Mayadev, J., Zamarin, D., Deng, W., Lankes, H., O’Cearbhaill, R., Aghajanian, C.A., et al. (2019) Anti-PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended-Field Chemoradiotherapy for Node-Positive Locally Advanced Cervical Cancer. International Journal of Gynecologic Cancer, 30, 701-704. [Google Scholar] [CrossRef] [PubMed]
[35] Monk, B.J., Toita, T., Wu, X., Vázquez Limón, J.C., Tarnawski, R., Mandai, M., et al. (2023) Durvalumab versus Placebo with Chemoradiotherapy for Locally Advanced Cervical Cancer (CALLA): A Randomised, Double-Blind, Phase 3 Trial. The Lancet Oncology, 24, 1334-1348. [Google Scholar] [CrossRef] [PubMed]
[36] Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva Galves, M.H., Ramos Elias, P., et al. (2023) LBA38 Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer: A Randomized, Double-Blind, Phase III Engot-CX11/GOG-3047/KEYNOTE-A18 Study. Annals of Oncology, 34, S1279-S1280. [Google Scholar] [CrossRef] 
[37] Rodrigues, M., Vanoni, G., Loap, P., Dubot, C., Timperi, E., Minsat, M., et al. (2023) Nivolumab Plus Chemoradiotherapy in Locally-Advanced Cervical Cancer: The NICOL Phase 1 Trial. Nature Communications, 14, Article No. 3698. [Google Scholar] [CrossRef] [PubMed]
[38] Wu, X., Xia, L., Zhang, K., Tang, Y., Zhang, G.N., Wang, D., et al. (2023) LBA44 Camrelizumab plus Famitinib versus Camrelizumab Alone and Investigator’s Choice of Chemotherapy in Women with Recurrent or Metastatic Cervical Cancer. Annals of Oncology, 34, S1284-S1285. [Google Scholar] [CrossRef] 
[39] Xu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., et al. (2022) Efficacy and Safety of Sintilimab plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. Journal of Clinical Oncology, 40, 1795-1805. [Google Scholar] [CrossRef] [PubMed]
[40] Oaknin, A., Gladieff, L., Martinez-Garcia, J., et al. (2023) Atezolizumab plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer (BEATcc): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 403, 31-43.
[41] Xu, Q., Liu, J., Li, L., Lin, Y., Chen, Y., Song, Y., et al. (2023) Penpulimab plus Platinum-Based Chemotherapy Combined with Anlotinib in First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer: A Single-Arm, Open-Label Phase Ⅱ Study (ALTN-AK105-II-06). Journal of Clinical Oncology, 41, e17512. [Google Scholar] [CrossRef] 
[42] Lan, C., Shen, J., Wang, Y., Li, J., Liu, Z., He, M., et al. (2020) Camrelizumab plus Apatinib in Patients with Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 38, 4095-4106. [Google Scholar] [CrossRef] [PubMed]

为你推荐